Trial Profile

A phase 1a randomized, single-blind, placebo-controlled, single-ascending dose, clinical study is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral TP-317 in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Magnesium lysinate bis resolvin E1 (Primary)
Indications Colorectal cancer; Crohn's disease; Pancreatic cancer; Ulcerative colitis
Focus Adverse reactions; First in man
Sponsors Thetis Pharmaceuticals

05 May 2025 Results presented in the Thetis Pharmaceuticals Media Release
05 May 2025 According to a Thetis Pharmaceuticals media release, data from the study were presented at Digestive Disease Week (DDW) 2025
30 Apr 2025 Results assessing pharmacokinetics, pharmacodynamics and safety profile of oral TP-317, presented at the 116th Annual Meeting of the American Association for Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com